NSE - Delayed Quote INR

Kilitch Drugs (India) Limited (KILITCH.NS)

462.30
+2.20
+(0.48%)
At close: May 23 at 3:29:27 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,811,451
1,536,062
1,388,582
1,129,584
681,283
Cost of Revenue
1,021,450
804,680
771,348
682,533
381,216
Gross Profit
790,001
731,382
617,234
447,051
300,067
Operating Expense
583,223
520,276
473,727
349,422
262,562
Operating Income
206,778
211,106
143,507
97,629
37,505
Net Non Operating Interest Income Expense
-44,614
-56,285
-47,812
-11,119
-7,066
Pretax Income
255,442
193,545
120,143
96,144
51,196
Tax Provision
75,251
57,793
37,316
34,007
13,529.90
Net Income Common Stockholders
195,123
146,014
104,481
73,672
36,711
Diluted NI Available to Com Stockholders
195,123
146,014
104,481
73,672
36,711
Basic EPS
12.14
9.17
6.71
4.73
2.37
Diluted EPS
12.14
9.17
6.71
4.73
2.37
Basic Average Shares
16,075.93
15,929.31
15,582.13
15,566.11
15,479.89
Diluted Average Shares
16,075.93
15,929.31
15,582.13
15,566.11
15,479.89
Rent Expense Supplemental
4,924
13,915
3,773
4,876
3,246
Total Expenses
1,604,673
1,324,956
1,245,075
1,031,955
643,778
Net Income from Continuing & Discontinued Operation
195,123
146,014
104,481
73,672
36,711
Normalized Income
185,449.03
136,395.03
98,840.30
67,843.10
30,348.46
Interest Income
1,642
4,079
3,017
2,191
1,703
Interest Expense
47,623
59,294
49,189
11,984
7,544
Net Interest Income
-44,614
-56,285
-47,812
-11,119
-7,066
EBIT
303,065
252,839
169,332
108,128
58,740
EBITDA
334,991
286,335
204,838
132,784
78,601
Reconciled Cost of Revenue
1,021,450
804,680
771,348
682,533
381,216
Reconciled Depreciation
31,926
33,496
35,506
24,656
19,861
Net Income from Continuing Operation Net Minority Interest
195,123
146,014
104,481
73,672
36,711
Total Unusual Items Excluding Goodwill
13,714
13,714
8,182
9,019
8,648
Total Unusual Items
13,714
13,714
8,182
9,019
8,648
Normalized EBITDA
321,277
272,621
196,656
123,765
69,953
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
4,040.03
4,095.03
2,541.30
3,190.10
2,285.46
3/31/2021 - 9/29/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

WANBURY.NS Wanbury Limited
287.48
-1.06%
 
UNICHEMLAB.NS Unichem Laboratories Limited
642.00
+2.65%
 
WINDLAS.NS Windlas Biotech Limited
917.40
-5.52%
 
VENUSREM.NS Venus Remedies Limited
355.60
+0.15%
 
LAURUSLABS.BO Laurus Labs Limited
593.15
+0.45%
 
SOLARA.NS Solara Active Pharma Sciences Limited
476.70
-0.03%
 
LINCOLN.NS Lincoln Pharmaceuticals Limited
558.65
+1.61%
 
KPL.BO Kwality Pharmaceuticals Limited
944.85
-0.60%
 
HIKAL.NS Hikal Limited
404.70
-0.46%
 
AKUMS.NS AKUMS DRUGS AND PHARMA L
566.05
+0.38%